

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
22 January 2009 (22.01.2009)

PCT

(10) International Publication Number  
**WO 2009/010770 A3**

(51) International Patent Classification:

A61K 9/00 (2006.01) A61K 31/31 (2006.01)  
A61K 31/00 (2006.01)

(21) International Application Number:

PCT/GB2008/002473

(22) International Filing Date:

18 July 2008 (18.07.2008)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

0714134.4 19 July 2007 (19.07.2007) GB

(71) Applicant (for all designated States except US): **NORTON HEALTHCARE LTD** [GB/GB]; Regent House, 5-7 Broadhurst Gardens, Swiss Cottage, London NW6 3RZ (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ZENG, Xian-Ming** [GB/GB]; 45 Hill Road, Mitcham, Surrey CR4 2HS (GB). **MARTIN, Gary, Peter** [GB/GB]; 47 South Way, Lewes, East Sussex BN7 1LY (GB). **MARRIOTT, Christopher** [GB/GB]; Glebe House, Church Street, Byfield, Northants NN11 6XN (GB). **TAKI, Mohammed** [GB/GB]; 50 Mersham Drive, Kingsbury, London NW9 9PN (GB).

(74) Agent: **COTTAM, David, William**; Teva Europe Patent Department, 167 Fleet Street, London EC4A 2EA (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(88) Date of publication of the international search report:

7 January 2010

(54) Title: DRY-POWDER MEDICAMENT



(57) Abstract: This invention relates to a dry powder medicament and particularly to a medicament which provides improved fine particle fraction. The method for preparing the inhalable dry-powder medicament comprises the steps of: (i) fractionating a particulate active ingredient based on aerodynamic particle size, (ii) recovering at least one fraction of the particulate active ingredient and (iii) combining the recovered fraction with a carrier to provide the inhalable dry-powder medicament. A dry-powder medicament per se is also described.



WO 2009/010770 A3

# INTERNATIONAL SEARCH REPORT

International application No  
PCT/GB2008/002473

**A. CLASSIFICATION OF SUBJECT MATTER**  
INV. A61K9/00      A61K31/00      A61K31/31

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SALEEM, I. ET AL: "Modulation of dry powder inhaler performance by controlling micronized drug particle size distributions" AAPS JOURNAL, vol. 8, no. S2, 2006, XP002510592 abstract	1, 2, 6-9, 13, 15, 16, 29, 30
Y		3-5, 10-12, 14, 17-28
Y	BOER, A.H. ET AL.: "Characterization of inhalation aerosols: a critical evaluation of cascade impactor and laser diffraction technique" INT. J. PHARM., vol. 249, 2002, pages 219-231, XP002510593 the whole document	1-30
	----- -/-- -----	

Further documents are listed in the continuation of Box C.

See patent family annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \* & \* document member of the same patent family

Date of the actual completion of the international search

2 November 2009

Date of mailing of the international search report

12/11/2009

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040  
Fax: (+31-70) 340-3016

Authorized officer

Raposo, Antonio

INTERNATIONAL SEARCH REPORT

International application No  
PCT/GB2008/002473

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	FENTON, C. ET AL: "Inhaled salmeterol/fluticasone propionate: a review of its use in chronic obstructive pulmonary disease" DRUGS, vol. 64, no. 17, 2004, pages 1975-1996, XP002510594 abstract	1-30
Y	MARKHAM, A. ET AL: "Inhaled salmeterol/fluticasone propionate combination: a pharmacoeconomic review of its use in the management of asthma" PHARMACOECONOMICS, vol. 18, 2000, pages 591-608, XP002510595 abstract	1-30